Publications by authors named "A Teixeira-Carvalho"
Introduction: The present study aimed at evaluating the systemic profile and network connectivity of immune mediators during acute chikungunya fever (CHIKF) according to days of symptoms onset and ageing.
Methods: A total of 161 volunteers (76 CHIKF patients and 85 non-infected healthy controls) were enrolled.
Results And Discussion: Data demonstrated that a massive and polyfunctional storm of serum immune mediators was observed in CHIKF.
Immunogenicity and Safety According to Immunosuppressive Drugs and Different COVID-19 Vaccine Platforms in Immune-Mediated Disease: Data from SAFER Cohort.
Vaccines (Basel)
December 2024
Background/objectives: The effectiveness of COVID-19 vaccine in patients with immune-mediated inflammatory diseases (IMID) depends on the underlying disease, immunosuppression degree and the vaccine regimens. We evaluate the safety and immunogenicity of different COVID-19 vaccine schedules.
Methods: The SAFER study: "Safety and effectiveness of the COVID-19 Vaccine in Rheumatic Disease", is a Brazilian multicentric prospective observational phase IV study in the real-life.
Article Synopsis
- The study examined how different immune responses, classified as persistent non-responders and responders, influence memory B-cell responses after Fluzone vaccination against H1N1.
- Persistent responders showed a significantly higher increase in specific B-cell populations compared to non-responders, who displayed a unique profile with increased transitional B-cells and IgM-expressing memory B-cells.
- The findings indicate a complex relationship between antibody titers and various memory B-cell types, suggesting that understanding these differences could enhance future vaccine development.
Phenotypic Timeline Kinetics, Integrative Networks, and Performance of T- and B-Cell Subsets Associated with Distinct Clinical Outcome of Severe COVID-19 Patients.
Microorganisms
November 2024
The present study aimed to evaluate the kinetics of the phenotypic profile and integrative networks of T/B-cells in severe COVID-19 patients, categorized according to disease outcome, during the circulation of the B.1.1.
View Article and Find Full Text PDFArticle Synopsis
- Identifying biomarkers for COVID-19 outcomes is essential for better managing high-risk patients and improving survival chances, particularly through early antiviral medication administration.
- A study involving 297 COVID-19 patients in Belo Horizonte, Brazil, explored the relationship between hematological parameters and disease severity using statistical analysis and machine learning.
- Findings indicate that monocyte percentage and granulocyte-to-lymphocyte ratio can effectively predict hospitalization risk, making these simple blood test parameters valuable tools for managing treatment in various healthcare settings.